<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115684">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01597193</url>
  </required_header>
  <id_info>
    <org_study_id>MDV3100-08</org_study_id>
    <nct_id>NCT01597193</nct_id>
  </id_info>
  <brief_title>Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer</brief_title>
  <official_title>A Phase 1 Open-Label, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enzalutamide (Formerly MDV3100) in Patients With Incurable Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medivation, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medivation, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability and pharmacokinetics of
      enzalutamide alone and in combination with anastrozole, or exemestane, or fulvestrant in
      patients with incurable breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of daily enzalutamide</measure>
    <time_frame>18 months</time_frame>
    <description>To evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) of enzalutamide in patients with incurable (Stage IV, or locally advanced unresectable) breast cancer;
To evaluate the safety and tolerability of daily enzalutamide at the recommended Phase 2 dose in patients with incurable androgen receptor positive (AR+) breast cancer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of daily enzalutamide plus anastrozole</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of daily enzalutamide plus exemestane 25 mg/day</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of daily enzalutamide plus exemestane 50 mg/day</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of daily enzalutamide plus fulvestrant</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic properties of enzalutamide</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic properties of enzalutamide plus anastrozole</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic properties of enzalutamide plus exemestane</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic properties of enzalutamide plus fulvestrant</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>enzalutamide (80-mg with increase to 160 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enzalutamide be provided as two or four 40-mg capsules by mouth daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>enzalutamide and anastrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with anastrozole (1 mg) administered as one 1-mg tablet by mouth once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>enzalutamide and exemestane 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with exemestane administered as one 25-mg tablet daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>enzalutamide and exemestane 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with exemestane administered as two 25-mg tablets daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>enzalutamide and fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with fulvestrant (500 mg) administered as two 250-mg intramuscular injections every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enzalutamide</intervention_name>
    <description>80 mg (2 capsules) or 160 mg (4 capsules) taken orally daily.</description>
    <arm_group_label>enzalutamide (80-mg with increase to 160 mg)</arm_group_label>
    <other_name>MDV3100, Xtandi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrozole</intervention_name>
    <description>1 mg/day</description>
    <arm_group_label>enzalutamide and anastrozole</arm_group_label>
    <other_name>Arimidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exemestane</intervention_name>
    <description>The exemestane dose is 25mg daily.</description>
    <arm_group_label>enzalutamide and exemestane 25 mg</arm_group_label>
    <other_name>Aromasin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fulvestrant</intervention_name>
    <description>500 mg every 28 days</description>
    <arm_group_label>enzalutamide and fulvestrant</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enzalutamide</intervention_name>
    <description>160 mg (4 capsules) taken orally daily.</description>
    <arm_group_label>enzalutamide and anastrozole</arm_group_label>
    <arm_group_label>enzalutamide and exemestane 25 mg</arm_group_label>
    <arm_group_label>enzalutamide and exemestane 50 mg</arm_group_label>
    <arm_group_label>enzalutamide and fulvestrant</arm_group_label>
    <other_name>MDV3100</other_name>
    <other_name>Xtandi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exemestane</intervention_name>
    <description>The exemestane dose is 50 mg daily.</description>
    <arm_group_label>enzalutamide and exemestane 50 mg</arm_group_label>
    <other_name>Aromasin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed breast cancer with accompanying pathology report;

          -  Submit unstained representative tumor specimen, either as a paraffin block
             (preferred) or â‰¥ 10 unstained slides

          -  Received at least 2 lines of systemic therapy in the advanced setting (for
             enzalutamide alone arm only);

          -  Eastern Cooperative Oncology Group performance (ECOG) status of 0 or 1;

          -  Estimated life expectancy of at least 3 months

        Exclusion Criteria:

          -  Severe concurrent disease, infection, or comorbidity that, in the judgment of the
             Investigator, would make the patient inappropriate for enrollment;

          -  Pregnant or lactating;

          -  Known or suspected brain metastasis or leptomeningeal disease;

          -  History of another malignancy within the previous 5 years other than curatively
             treated in situ carcinomas;

          -  For patients who are enrolled to receive enzalutamide plus anastrozole or exemestane
             or fulvestrant must not have received tamoxifen or any medication known to be a
             potent CYP3A4 inducer or inhibitor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Medivation, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 5, 2016</lastchanged_date>
  <firstreceived_date>May 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>enzalutamide</keyword>
  <keyword>MDV3100</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
